{"id":"jnj16269110","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Glucagon is a hormone that raises blood glucose levels by stimulating glycogenolysis and gluconeogenesis. By blocking glucagon receptors, JNJ16269110 reduces blood glucose levels, making it a potential treatment for type 2 diabetes.","oneSentence":"JNJ16269110 is a selective and potent antagonist of the human glucagon receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:57:45.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00672386","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases","enrollment":352},{"nctId":"NCT00622765","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-11","conditions":"Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases","enrollment":321},{"nctId":"NCT01041677","phase":"PHASE2","title":"A Study of the Safety of R256918 in Obese Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-02","conditions":"Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases","enrollment":71}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"JNJ16269110","genericName":"JNJ16269110","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNJ16269110 is a selective and potent antagonist of the human glucagon receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}